South Korea Biologics Market Size, Share, and COVID-19 Impact Analysis, By Source (Microbial, Mammalian, and Others), By Product (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Antisense, RNAi and Molecular Therapy, and Others), and South Korea Biologics Market Insights, Industry Trend, Forecasts to 2035

South Korea Biologics Market Insights Forecasts to 2035

• The South Korea Biologics Market Size was estimated at USD 6,196.4 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 7.06% from 2025 to 2035
• The South Korea Biologics Market Size is Expected to Reach USD 13,124.9 Million by 2035

According to a research report published by Spherical Insights & Consulting, the South Korea Biologics Market is anticipated to reach USD 13,124.9 million by 2035, growing at a CAGR of 7.06% from 2025 to 2035. Some of the major factors propelling the market include the growing government's significant investments in biotechnology and life sciences, the growing strategic partnerships with multinational biopharmaceutical companies, and the global trend toward personalized medicine.

Market Overview

The South Korea biologics market encompasses the research, development, production, and marketing of biologic medications made from living things are all included in the South Korean biologics market. These medications are used to treat a variety of illnesses, including cancer, autoimmune conditions, and infectious diseases. They include monoclonal antibodies, recombinant proteins, vaccines, gene therapies, and cell-based therapies. Additionally, a noteworthy trend is South Korea's strategic partnerships with international biopharmaceutical firms, which aid in the transfer of technology and knowledge and strengthen domestic capacities in biologics manufacturing and research. In addition, the South Korean government's increase in healthcare spending and insurance coverage for biologic treatments is driving the market. Alongside this, the market is being greatly aided by the quick development of biotechnology, such as gene editing and cell therapy. Alongside this advancement, there has been a surge in biologics research and clinical trials, concentrating on a variety of therapeutic areas. Further, fostering a biotech-friendly ecosystem and proactively adjusting to new technologies are key factors propelling growth and innovation in South Korea's biologics market. Technological developments and shifting consumer preferences are a couple of the other factors propelling the market.

Report Coverage

This research report categorizes the market for the South Korea biologics market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the South Korea biologics market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the South Korea biologics market.

Driving Factors

The government's large investments in biotechnology and life sciences are the main factors driving the biologics market in South Korea. Through the promotion of biopharmaceutical research, development, and commercialization, this vision seeks to strengthen South Korea's standing as a major biologic’s hub. In addition, as South Korea's population ages, there is a growing need for cutting-edge treatment options, such as biologics, to address age-related and chronic illnesses. Strong intellectual property laws and regulations in the nation encourage innovation and draw in foreign capital. Furthermore, the development and production of biologics are greatly aided by South Korea's highly qualified workforce and sophisticated technological infrastructure. The South Korean biologics market is expanding as a result of the trend toward personalized medicine. Biologics provide the accuracy and effectiveness needed for more individualized treatment plans as the healthcare industry shifts to these methods.

Restraining Factors

Biologics, especially monoclonal antibodies and vaccines, are becoming more and more in demand. However, scaling production to meet this demand is a challenge for many CMOs. Bottlenecks are frequently caused by the intricacy of the production of biologics, including the use of mammalian cell cultures and purification procedures. These time-consuming and resource-intensive production methods restrict the market's capacity to take full advantage of expansion prospects.

Market Segmentation

The South Korea biologics market share is classified into source and product.

• The microbial segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea biologics market is segmented by source into microbial, mammalian, and others. Among these, the microbial segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. The segmental growth due to their affordability, scalability, and effectiveness in creating therapeutic proteins and vaccines, microbial biologics are utilized extensively.

• The monoclonal antibodies segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea biologics market is segmented by product into monoclonal antibodies, vaccines, recombinant proteins, antisense, RNAi and molecular therapy, and others. Among these, the monoclonal antibodies segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. The segmental growth due to their high specificity, ability to treat chronic illnesses, and increasing use in immunology and oncology treatments, these biologics are widely used.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the South Korea biologics market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Samsung Bioepis
• Celltrion
• Medipost
• Cha Biotech
• Alteogen
• Others

Recent Developments:

• In February 2025, South Korea has rapidly emerged as a powerhouse in the global biopharmaceutical landscape, transforming itself from a generic drug manufacturer to a pioneering therapeutic developer making impressive advancements in cell and gene therapy and biosimilars. And this presents huge potential for international companies innovating in these fields.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at South Korea, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the South Korea Biologics Market based on the below-mentioned segments:

South Korea Biologics Market, By Source

• Microbial
• Mammalian
• Others

South Korea Biologics Market, By Product

• Monoclonal Antibodies
• Vaccines
• Recombinant Proteins
• Antisense
• RNAi and Molecular Therapy
• Others